Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERFERON TREATMENT FOR CHRONIC HEPATITI S-C IN PATIENTS INFECTED BYTHE HUMAN-IMMUNODEFICIENCY-VIRUS
Autore:
SORIANO V; GARCIASAMANIEGO J; BRAVO R; GONZALEZ J; CASTRO A; MARTINEZODRIOZOLA P; COLMENERO M; CARBALLO E; SUAREZ D; CASTILLA J; RODRIGUEZPINERO FJ; MORENO A; DELROMERO J; PEDREIRA J; GONZALEZLAHOZ J;
Indirizzi:
RAFAEL CALVO 7,2A E-28010 MADRID SPAIN INST SALUD CARLOS 3,CTR INVEST CLIN MADRID SPAIN HOSP JUAN CANALEJO LA CORUNA SPAIN HOSP CALELLA BARCELONA SPAIN HOSP BASURTO BILBAO SPAIN HOSP LA PAZ MADRID SPAIN HOSP VIRGEN MACARENA SEVILLE SPAIN HOSP XERAL GALICIA SANTIAGO SPAIN CTR SANDOVAL,COMUNIDAD MADRID MADRID SPAIN HOSP ARQUITECTO MARCIDE EL FERROL SPAIN CPS,AYUNTAMIENTO MADRID MADRID SPAIN CTR NACL EPIDEMIOL,INST SALUD CARLOS 3 MADRID SPAIN REG TRANSFUS CTR,COMUNIDAD MADRID MADRID SPAIN HOSP GEN GREGORIO MARANON MADRID SPAIN
Titolo Testata:
Medicina Clinica
fascicolo: 13, volume: 106, anno: 1996,
pagine: 486 - 490
SICI:
0025-7753(1996)106:13<486:ITFCHS>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ITA
Soggetto:
NON-B-HEPATITIS; RECOMBINANT ALPHA-INTERFERON; PLACEBO-CONTROLLED TRIAL; HIV-POSITIVE PATIENTS; CHRONIC NON-A; NATURAL-HISTORY; ALFA THERAPY; ZIDOVUDINE; AIDS; GENOTYPES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
64
Recensione:
Indirizzi per estratti:
Citazione:
V. Soriano et al., "INTERFERON TREATMENT FOR CHRONIC HEPATITI S-C IN PATIENTS INFECTED BYTHE HUMAN-IMMUNODEFICIENCY-VIRUS", Medicina Clinica, 106(13), 1996, pp. 486-490

Abstract

BACKGROUND: Alfa-interferon (aIFN) is widely recommended for the treatment of chronic hepatitis C (CHC). Hepatitis C virus (HCV) infection is very common in injecting drug users (IDUs), which in Spain represent the large number of HIV-infected persons. interaction between human immunodeficiency virus (HIV) and HCV in coinfected patients might accelerate the clinical course of HCV-associated liver disease. The efficacy and safety of alFN therapy in HIV-infected patients with CHC is notwell known. PATIENTS AND METHODS: In a multicenter, prospective, open, non randomized and partially controlled study, we compared the efficacy and safety of alFN therapy in 119 patients with CHC, of whom 90 were HIV-positive and 29 HIV-negative. Interferon was started at 5 mega U tiw for 3 months, followed in responders by 3 megaU tiw for additional 9 months. RESULTS: One hundred seven patients completed the study. A normalization of the aminotransferase values at the end of treatment(complete response, CR) was observed in 26/80 (32.5%) HIV-positive and 10/27 (37.0%) HIV-negative individuals (p = 0.666). Relapses at 12 months of stopping alFN were seen in 30.8% of HIV-positive subjects and12.5% of HIV-negatives (p = 0.403). Side effects were uncommon and did not have severity; only one patient required to stop the medication. However, 3 HIV-positive subjects treated with alFN (3.5% of them) showed an irreversible fall of CD4+ T-cells below half the baseline values. CONCLUSION: HIV-infected patients with CHC seems to respond to alFNwith a similar rate than HIV-negatives. Moreover, the drug is similarly well tolerated in both groups of patients, although a fall of CD4+ T-cells is an unusual side effect of particular relevance observed in HIV-infected patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 05:41:48